Abstract
Both azathioprine and its active metabolite, 6-mercaptopurine, are of benefit in the treatment of inflammatory bowel disease, either in resistant cases, or for their steroid-sparing effect. Azathioprine treatment is limited in some patients by hypersensitivity reactions or other side effects. We report our experience in 11 patients previously unable to tolerate azathioprine for a variety of reasons, who were switched to 6-mercaptopurine. Of seven patients with ulcerative colitis and four patients with Crohn's disease who were treated with 6-mercaptopurine following failed azathioprine therapy, six were able to successfully tolerate the substitute medication, with good response. Where patients have previously been intolerant of azathioprine yet ongoing indications for immunosuppressive therapy remain, a trial of 6-mercatopurine may be warranted. Given the similar efficacies of the two drugs in inflammatory bowel disease, these findings also favor the use of 6-mercaptopurine rather than the parent compound as initial therapy.
Similar content being viewed by others
REFERENCES
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37:674-678, 1995
Present D, Korelitz B, Wisch N, Glass J, Sachar D, Pasternack B: Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302:981-987, 1980
Pearson D, May G, Fick G, Sutherland L: Azathioprine and 6-mercaptopurine in Crohn Disease. A meta-analysis. Ann Intern Med 122:132-142, 1995
Sandborn W: A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporin, and methotrexate. Am J Gastroenterol 91:423-433, 1996
Present D, Meltzer S, Krumholz M, Wolke A, Korelitz B: 6-Mercaptopurine in the management of inflammatory bowel disease: Short-and long-term toxicity. Ann Intern Med 111:641-649, 1989
Cox J, Daneshmend T, Hawkey C, Logan F, Walt R: Devastating diarrhoea caused by azathioprine: Management difficulty in inflammatory bowel disease. Gut 29:686-688, 1988
Lawson D, Lovatt G, Gurton C, Hennings R: Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev 3:161-171, 1984
King J, Laver M, Fairley K: Sensitivity to azathioprine. Med J Aust 2:939-941, 1972
Davis M, Eddleston A, Williams R: Hypersensitivity and jaundice due to azathioprine. Postgrad Med J 56:274-275, 1980
Mahmoud A, Willoughby J: Azathioprine and 6-mercaptopurine are not necessarily interchangeable in the treatment of Crohn's disease. Gastroenterology 108:A868, 1995
Pratt D, Flavin D, Kaplan M: The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110:271-274, 1996
Colonna T, Korelitz B: The role of leukopaenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 89:362-366, 1994
Lémann M, Bouhnik Y, Kmieciak-Le Corguille M, Bonnet J, Coffin B, Marteau P, Bitoun A, Messing B, Jian R, Matuchansky C, Modigliani R, Rambaud J: Treatment of Crohn's disease (CD) with 6-mercaptopurine (6-MP) in patients intolerant to azathioprine (AZA). Gastroenterology 112:A1025, 1997
Calne R, Alexander G, Murray J: A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann NY Acad Sci 99:743-761, 1962
Elion G: The pharmacology of azathioprine. Ann NY Acad Sci 685:400-407, 1993
Dalke A, Kazmers I, Kelly W: Hypoxanthine-guanine phosphoribosyltransferase-independent toxicity of azathioprine in human lymphoblasts. Biochem Pharmacol 33:2692-2695, 1984
Dayton J, Turka L, Thompson C, Mitchell B: Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 41:671-676, 1992
St Georgiev V: Enzymes of the purine metabolism: inhibition and therapeutic potential. Ann NY Acad Sci 685:207-216, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bowen, D.G., Selby, W.S. Use of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease Previously Intolerant of Azathioprine. Dig Dis Sci 45, 1810–1813 (2000). https://doi.org/10.1023/A:1005569808947
Issue Date:
DOI: https://doi.org/10.1023/A:1005569808947